BioSpace News Archive

Drug Development

Versanis Presents Data Demonstrating Bimagrumab Treatment Leads to Substantial Fat Mass Loss Coupled with Lean Mass Gain in Diabetic and Non-Diabetic Patients

Versanis Bio will share analysis of Phase 2 data from prior studies of lead asset bimagrumab at ENDO 2022, being held virtually and in Atlanta June 11-14, 2022.

June 11, 2022
·
3 min read
Drug Development

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

CRISPR Therapeutics presented positive results from the Company’s ongoing Phase 1 COBALT™-LYM trial evaluating the safety and efficacy of CTX130™, its wholly-owned allogeneic CAR-T cell therapy targeting CD70 for the treatment of both solid tumors and certain hematologic malignancies.

June 11, 2022
·
12 min read
Pharm Country

Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia

Positive results from the global pivotal QuANTUM-First phase 3 trial of Daiichi Sankyo’s quizartinib combined with standard induction and consolidation chemotherapy and then continued as a single agent demonstrated a statistically significant and clinically meaningful improvement in overall survival in adult patients aged 18-75 with newly diagnosed FLT3-ITD positive acute myeloid leukemia compared to standard chemotherapy alone.

June 11, 2022
·
9 min read
Drug Development

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S announced primary results from the large B-cell lymphoma expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluating subcutaneous epcoritamab, an investigational bispecific antibody.

June 11, 2022
·
10 min read
BioMidwest

Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)

Horizon Therapeutics plc announced results of a new analysis examining rates of hyperglycemia among patients treated with TEPEZZA for TED compared to placebo in the Phase 2 and OPTIC Phase 3 clinical trials.

June 11, 2022
·
8 min read
Drug Development

AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress

AbbVie announced primary results from the large B-cell lymphoma expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluating epcoritamab, an investigational subcutaneous bispecific antibody.

June 11, 2022
·
9 min read
Genetown

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announce presentation of new data on exa-cel, formerly known as CTX001™, from CLIMB-111, CLIMB-121 and CLIMB-131 highlighting the potentially transformative profile of this investigational therapy for people with transfusion-dependent beta thalassemia or severe sickle cell disease and provided additional program updates.

June 11, 2022
·
17 min read
Biotech Beach

Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022

Orphagen Pharmaceuticals announced that additional data from its preclinical program to develop OR-449 for the treatment of adrenocortical cancer was presented at the 104th Annual Meeting of the Endocrine Society being held in Atlanta from June 11 to 14.

June 11, 2022
·
3 min read